Share on StockTwits

ImmunoCellular Therapeutics (NASDAQ:IMUC) CEO Andrew Gengos acquired 10,000 shares of the company’s stock in a transaction that occurred on Thursday, August 14th. The stock was purchased at an average cost of $0.90 per share, for a total transaction of $9,000.00. Following the acquisition, the chief executive officer now directly owns 37,000 shares in the company, valued at approximately $33,300. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of ImmunoCellular Therapeutics (NASDAQ:IMUC) opened at 0.90 on Friday. ImmunoCellular Therapeutics has a 1-year low of $0.65 and a 1-year high of $4.00. The stock’s 50-day moving average is $1.00 and its 200-day moving average is $1.17. The company’s market cap is $52.1 million.

ImmunoCellular Therapeutics (NASDAQ:IMUC) last released its earnings data on Monday, August 11th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.02. On average, analysts predict that ImmunoCellular Therapeutics will post $-0.22 earnings per share for the current fiscal year.

IMUC has been the subject of a number of recent research reports. Analysts at Roth Capital upgraded shares of ImmunoCellular Therapeutics from a “neutral” rating to a “buy” rating in a research note on Monday, June 2nd. They now have a $3.00 price target on the stock, up previously from $2.00. Analysts at Maxim Group cut their price target on shares of ImmunoCellular Therapeutics from $12.00 to $4.00 in a research note on Monday, June 2nd. They now have a “buy” rating on the stock. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $3.31.

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.